España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Spinnaker ETF Series Genter Capital Taxable Quality Intermediate ETF
GENT
ARCA
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$10.19
-0.0050
-0.05%
At close: -
Get Report
Comment
Overview
News
Holdings
Dividends
Short Interest
Latest news for Spinnaker ETF Series Genter Capital Taxable Quality Intermediate ETF (ARCA:GENT)
Spinnaker ETF Series Genter Capital Taxable Quality Intermediate ETF (ARCA: GENT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, March 31, 2014
Jazz Pharmaceuticals, Gentium Announce Europe...
Benzinga
Wednesday, January 15, 2014
Gentium Holders Sue to Stop Jazz Pharma Purch...
Benzinga
Friday, December 20, 2013
Market Wrap For December 20: Markets Gain On GDP Data
Benzinga
Mid-Afternoon Market Update: Textron Rises as Markets Rise Across the Board
Benzinga
Mid-Day Market Update: Red Hat Surges On Upbeat Results; CarMax Shares Decline
Benzinga
Mid-Morning Market Update: Markets Rally; BlackBerry Posts Q3 Loss
Benzinga
Gentium Spikes Higher
Benzinga
Wedbush Downgrades Gentium SpA to Neutral, Lowers PT to $57.00
Benzinga
ETF Outlook for Friday, December 20 (REM, USO, IBB, FCG)
Benzinga
Thursday, December 19, 2013
Benzinga's M&A Chatter for Thursday December 19, 2013
Benzinga
Gentium Shares Resume Trade, Now Up 0.4%
Benzinga
Shares of Gentium Open for Trade, Not Yet See...
Benzinga
PREVIEW: Gentium to Resume Trading at 5:15 PM...
Benzinga
Jazz Pharmaceuticals Trading at $118 Followi...
Benzinga
Jazz Pharmaceuticals to Acquire Gentium for $57.00/Share
Benzinga
Tuesday, November 19, 2013
Gentium Receives EMA Orphan Drug Designation for Defibrotide
Benzinga
Tuesday, November 12, 2013
Gentium Successfully Completes Defibrotide Phase 1 Study in Japan
Benzinga
Thursday, October 31, 2013
GentiumReports Q3 EPS of $0.22 vs $0.18 Est; Revenue of $15.68M vs $13.50M Est
Benzinga
Tuesday, October 22, 2013
Gentium Receives EC Marketing Authorization for Defitelio
Benzinga
Wednesday, October 02, 2013
Salvatore Calabrese Named COO at Gentium
Benzinga
Monday, September 30, 2013
Wedbush Maintains Outperform on Gentium SpA, Raises PT to $35.00
Benzinga
Friday, July 26, 2013
Gentium Receives Positive Opinion From EMA's CHMP for Defitelio
Benzinga
Tuesday, June 04, 2013
Gentium Requests Re-Examination of Negative Opinion of Defibrotide MAA by EMA
Benzinga
Tuesday, May 14, 2013
Earnings Scheduled For May 14, 2013
Benzinga
Tuesday, April 16, 2013
A Peek Into The Market Before The Trading Starts
Benzinga
Gentium Requests Re-Examination of Negative CHMP Opinion on Defibrotide
Benzinga
Thursday, March 28, 2013
Gentium SpA Reports Q4 EPS of $0.04 vs $(0.03) Est; Revenue of $7.49M vs $8.57M Est
Benzinga
Gentium Reports Q4 EPS €0.04, Plans to Appeal...
Benzinga
Earnings Scheduled For March 28, 2013
Benzinga
Friday, March 22, 2013
Gentium Shares Resume Trading Down 16%
Benzinga
CHMP Gives Negative Opinion on Gentium's Defibrotide for VOD; Shares to Resume at 9AM EST
Benzinga
Gentium Halted News Pending
Benzinga
Thursday, January 17, 2013
Gentium's MAA for Defibrotide to be on CHMP Agenda February 18-21, 2013
Benzinga
Wednesday, September 26, 2012
Gentium Provides Update on the Review of Defibrotide Marketing Authorization Application
Benzinga
Thursday, September 13, 2012
Earnings Scheduled For September 13, 2012
Benzinga
Friday, June 29, 2012
Lloyds, Luxottica and Other European Stocks Worth a Look
Benzinga
Thursday, June 21, 2012
Gentium Submits Day 180 Response to List of Outstanding Issues Received From the EMA's CHMP for Defibrotide MAA
Benzinga
Friday, May 04, 2012
Gentium Receives Day 180 List of Outstanding Issues From the CHMP for Defibrotide MAA
Benzinga
Wednesday, April 04, 2012
UPDATE: Brean Murray Carret Initiates Coverage on Gentium S.p.A.
Benzinga
Brean Murray Carret & Co. Initiates Coverage ...
Benzinga
Tuesday, March 27, 2012
Earnings Scheduled For March 27
Benzinga
Thursday, December 29, 2011
Gentium Provides Update on MAA Process for Defibrotide in Europe
Benzinga
Monday, December 12, 2011
Results From Gentium's Treatment IND for Defibrotide Presented at the American Society of Hematology Annual Meeting
Benzinga
Thursday, December 08, 2011
Gentium Announces Changes to Board of Directors
Benzinga
Wednesday, August 17, 2011
Wi Lan and Gentium Resumes Trading
Benzinga
PREVIEW: Gentium to Resume Trading at 4:45 p....
Benzinga
Gentium Withdraws New Drug Application for Defibrotide
Benzinga
Gentium Spa Halted, Pending News
Benzinga
Wednesday, July 06, 2011
Gentium Submits New Drug Application to FDA
Benzinga
Tuesday, June 21, 2011
Gentium Signs License and Distribution Agreement for Defibrotide With Medison Pharma Ltd. in Israel and the Palestinian Authority
Benzinga
Show More